Inclusion Criteria:

          1. Diagnosis of ductal adenocarcinoma of the pancreas (PDAC).

          2. Low tumor burden with at least one lesion that is suitable for image-guided
             intratumoral injection and needle biopsy.

          3. The patient is not eligible for a complete surgical resection of their disease as
             evaluated by a radiologist and/or surgeon.

          4. Patients who may receive the injections endoscopically should be eligible for
             sedation.

          5. The patient must be eligible for standard of care treatment with gemcitabine
             +nab-paclitaxel.

          6. Age ≥ 18 yrs of age

          7. Females of childbearing potential must have a negative pregnancy test and agree to use
             contraception during on-study protocol treatment.

          8. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.

          9. Absolute neutrophil count (ANC) ≥1.0 x 10^9/l, hemoglobin ≥9 g/dl, platelet count ≥
             100 x 10^9/l, prothrombin (INR) <1.5.

         10. Adequate hepatic function, with bilirubin < 1.5 x the ULN, and AST and ALT < 2.5 x ULN

         11. Adequate renal function with serum creatinine <2 x the ULN or creatinine clearance >30
             mL/min

         12. The patient must provide informed consent.

        Exclusion Criteria:

          1. Any concurrent treatment that would compromise the study including but not limited to
             continuous high dose corticosteroids (>10 mg/day of prednisone equivalence),
             lymphodepleting antibodies or cytotoxic agents.

          2. Treatment with high dose immune inhibitors including lymphotoxic monoclonal antibodies
             such as alemtuzumab (Campath), or rapamycin/rapalogs or cytotoxic agents within 21
             days of registration

          3. Treatment with biologic therapy within 21 days of registration.

          4. Use of any investigational agents within 21 days of registration.

          5. The use of systemic immunostimulatory agents (including, but not limited to,
             interferons and IL-2) are prohibited within 4 weeks or 5 half-lives of the drug
             (whichever is longer) prior to initiation of study treatment and during study
             treatment because these agents could potentially increase the risk for autoimmune
             conditions when given in combination with atezolizumab

          6. Pregnant or breastfeeding females.

          7. Known active hepatitis B or C infection, HIV infection or tuberculosis.

          8. Patients with active autoimmune disease or immune deficiency or previous
             Guillain-Barre syndrome. Patients with eczema, psoriasis, lichen simplex chronicus or
             vitiligo with dermatologic manifestations only (e.g. patients with psoriatic arthritis
             are excluded) are eligible for the study provide all of the following conditions are
             met:

               -  Rash must cover <10% of body surface area

               -  Disease is well controlled at baseline and requires only low-potency topical
                  corticosteroids

               -  No occurrence of acute exacerbations of the underlying condition requiring
                  psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents,
                  oral calcineurin inhibitors or high-potency or oral corticosteroids within the
                  previous 12 months

          9. Uncontrolled intercurrent illness including but not limited to psychiatric
             illness/social situations that in the opinion of the Investigator would compromise
             compliance of study requirements or put the patient at unacceptable risk.

         10. Other malignancies within the past 2 years (not including basal cell carcinoma of the
             skin, prostate cancer or in situ cervix carcinoma).

         11. Moderate to large volume ascites.

         12. History of leptomeningeal disease.

         13. Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent
             drainage procedures (once monthly or more frequently)

         14. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis or evidence of active
             pneumonitis on screening chest computed tomography (CT) scan. However, history of
             radiation pneumonitis in the radiation field (fibrosis) is permitted.

         15. Unstable angina, uncontrolled cardiac arrhythmia, recent (within 3 months) history of
             myocardial infarction or stroke or New York Class III/IV congestive heart failure

         16. Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation
             of study treatment or anticipation of need for a major surgical procedure during the
             study.

         17. Prior allogeneic stem cell or solid organ transplantation.

         18. History of severe allergic anaphylactic reactions to chimeric human or humanized
             antibodies or fusion proteins.

         19. Known hypersensitivity to CHO cell products or any component of the atezolizumab
             formulation.

         20. Live attenuated vaccines (e.g. FluMist) are prohibited within 4 weeks prior to
             initiation of study treatment, during atezolizumab treatment, and for 5 months after
             the final dose of atezolizumab.